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Abstract
Elevated levels of reactive oxygen species are found in most oncogenically transformed cells and 
are proposed to promote cellular transformation through mechanisms such as inhibition of 
phosphatases. BCR-ABL, the oncoprotein associated with the majority of chronic myelogenous 
leukemias, induces accumulation of intracellular ROS causing enhanced signaling downstream of 
PI3K. Previously we have shown that the transcription factor NF-κB is activated by BCR-ABL 
expression and is required for BCR-ABL-mediated cellular transformation. Inhibition of IKKβ and 
NF-κB leads to cell death through an unknown mechanism. Here, we analyze the potential 
involvement of NF-κB in moderating BCR-ABL-induced ROS levels to protect from death in 
response to cell stress. The data confirm that BCR-ABL promotes ROS levels and demonstrate 
that NF-κB prevents excessive ROS levels. Inhibition of NF-κB leads to an increase in ROS levels 
and to cell death controlled through ROS-induced JNK activity. The data demonstrate that one 
function for NF-κB in oncogenesis is the suppression of oncoprotein-induced ROS levels and that 
inhibition of NF-κB in some cancers, including CML, will increase ROS levels and promote cell 
death.
Introduction
Chronic myeloid leukemia is a malignant clonal disorder of hematopoietic stem cells that 
results in increased and deregulated growth of myeloid cells (Sawyers, 1999). 
Approximately 95% of CML cases arise from the formation of the Philadelphia (Ph) 
chromosome, a product of a chromosomal translocation that brings together the c-abl gene 
on chromosome 9 and the bcr gene on chromosome 22. This translocation results in the 
creation of the BCR-ABL fusion protein, which is a constitutively active tyrosine kinase 
(Sawyers, 1999). As a consequence of increased tyrosine kinase activity, BCR-ABL 
phosphorylates substrates including Grb2, Crkl and Shc, and activates signaling cascades, 
such as the Ras pathway, PI3K/Akt and Stat5, affecting the growth and differentiation of 
myeloid cells (Diaz-Blanco et al., 2007).
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NF-κB is a transcription factor comprised of five family members: p65 (RelA), RelB, c-Rel, 
p50/p105 (NF-κB1) and p52/p100 (NF-κB2). These proteins share a conserved Rel 
homology domain, which controls DNA binding, dimerization and interaction with 
inhibitory IκB proteins (Bassères and Baldwin, 2006; Courtois and Gilmore, 2006). NF-κB 
activation typically occurs through one of two distinct pathways. In the classical pathway, 
the p50-p65(RelA) heterodimer is activated by the IκB kinase (IKK) complex, which 
contains two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ. IKK 
phosphorylates IκBα, an inhibitory protein that normally sequesters p50-p65 in the 
cytoplasm, causing it to become ubiquitinated and subsequently degraded, allowing NF-κB 
to accumulate in the nucleus. In the alternative pathway, IKKα homodimers are activated 
and subsequently phosphorylate p100. This results in the proteolytic processing of p100 to 
p52 and allows p52-RelB dimers to translocate to the nucleus (Hayden and Ghosh, 2004). 
Once in the nucleus, NF-κB is known to regulate the expression of a variety of genes, 
including those encoding cytokines and cytokine receptors, inflammatory mediators, and 
antiapoptotic proteins (Bassères and Baldwin, 2006).
NF-κB is activated in many solid tumors (Basséres and Baldwin, 2006) and hematologic 
malignancies, including CML (Braun et al., 2006), where it provides proliferative and cell 
survival mechanisms. NF-κB is activated by BCR-ABL and is required for cellular 
transformation and tumor formation induced by this oncoprotein (Hamdane et al., 1997; 
Reuther et al. 1998). Inhibition of IKK in BCR-ABL-expressing cells induces death (Cilloni 
et al., 2006; Duncan et al., 2008). Interestingly, Imatinib- and/or Dasatinib-resistant cells 
were shown to be susceptible to IKKβ inhibition (Duncan et al, 2008), suggesting a novel 
therapeutic option for CML. However, the mechanism whereby IKKβ inhibition induces 
death of BCR-ABL-expressing cells has not been determined.
c-Jun N-terminal kinase (JNK), also known as stress-activated protein kinase (SAPK), is a 
member of the MAPK family and is involved in the regulation of c-jun, a component of the 
AP-1 family of transcription factors (Leppä and Bohmann, 1999). JNK is predominately 
activated by cellular stress mechanisms, including increased levels of reactive oxygen 
species (ROS), but can also be activated by other stimuli including cytokines and oncogenic 
transformation. JNK is actived by MAPKKs through the phosphorylation of threonine 183 
and tyrosine 185. JNK then phosphorylates c-Jun at serines 63 and 73 causing an increase in 
c-Jun transcriptional activity (Gupta et al., 1996). c-Jun activity is implicated in cell 
transformation, proliferation and death downstream of JNK (Leppä and Bohmann, 1999; 
Vogt, 2001). Interestingly, both c-jun and JNK are required for transformation of 
hematopoietic cells by BCR-ABL (Raitano et al., 1995) as well as their survival after 
transformation (Hess et al., 2002). However, under stimuli that induce cell stress, JNK 
activation can lead to death (Shen and Liu, 2006; Dhanasekaran and Reddy, 2008). JNK 
becomes activated by stimuli in a constitutive manner through increased intracellular ROS 
and activates apoptotic and necrotic death pathways (Tang et al, 2002; Pham et al, 2004; 
Ventura et al., 2004; Kamata et al, 2005).
It has been demonstrated that oncogenic transformation results in increased levels of 
intracellular ROS, which are used as secondary signaling molecules to increase proliferation 
and to promote the oncogenic potential of transformed cells (Pelicano et al., 2004; Benhar et 
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al., 2002). For example, oncogenic Ras leads to increased levels of ROS, which are 
important in oncogenic transformation and proliferation (Irani et al., 1997). Previous reports 
have shown that hematopoietic cell lines transformed with BCR-ABL have increased levels 
of intracellular ROS (Sattler et al, 2000; Kim et al, 2005; Naughton et al., 2009). ROS 
promotes PI3K-induced signaling downstream of BCR-ABL by inhibiting phosphatases 
which normally limit signal transduction cascades (Naughton et al., 2009), thereby 
increasing tumorigenicity.
Here we have explored the potential involvement of NF-κB in moderating intracellular ROS 
levels downstream of BCR-ABL. The results indicate that NF-κB activity functions to 
suppress BCR-ABL-induced ROS levels. Additionally, inhibition of IKK or NF-κB leads to 
enhanced ROS levels and elevated JNK activity to promote cell death. The experiments 
reveal a key pro-oncogenic mechanism and demonstrate a mechanism whereby inhibition of 
NF-κB activity promotes cytotoxicity of certain cancer cells.
Materials and Methods
Cell lines
32D and Ba/F3 hematopoietic murine cells were maintain in RPMI 1640 medium (Gibco) 
supplemented with 10% FBS and 10% Wehi-conditioned media as a source of IL-3. 32D 
and Ba/F3 cells stably expressing p185 or p210 BCR-ABL, respectively, were maintained in 
RPMI 1640 supplemented with 10% FBS. 293Ts were maintained in DMEM supplemented 
with 10% FBS.
Chemicals
2′,7′-Dichlorodihydrofluorescein Diacetate (DCF-DA; Calbiochem) was dissolved in 
DMSO. Catalse and n-acetyl-cysteine (Sigma) were dissolved in culture media. The pH of 
NAC was then adjusted to 7.2 and the stock was subsequently passed through a 0.2μm filter. 
Butylated hydroxyanisole (Sigma) was dissolved in ethanol. Compound A, SP600125 
(Sigma) and Z-VAD-FMK (Sigma) were dissolved in DMSO. All stocks were diluted to 
working dilutions in culture media.
Detection of ROS
Cells were harvested, washed twice with PBS, and then incubated with DCF-DA at a final 
concentration of 10μM for 15 minutes at 37°C in the dark. Cells were then washed once with 
PBS and analyzed immediately by flow cytometry.
Cell death staining
Cells were harvested and washed twice with cold PBS. 5×105 cells were resuspended in 100 
μl Annexin binding buffer (BD Pharmagen) and stained with Annexin V (BD Pharmagen; 
1:20) and 7-Amino-actinomycin D (BD Pharmigen; 1:50) or Propidium Iodide (BD 
Pharmigen; 1:20) at RT in the dark for 15 minutes. 400μl binding buffer was subsequently 
added and the cells were analyzed immediately by flow cytometry.
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Phospho-JNK (T183/Y185), JNK, Phospho-c-jun (S73), c-jun, and cleaved caspase 3 
(Asp175), caspase 3 and IκBα were obtained from Cell Signaling Technologies. β-tubulin 
was obtained from Santa Cruz Biotechnology. β-actin was obtained from Calbiochem.
Western blotting
Cells were harvested, washed twice with cold PBS and resuspended in lysis buffer (50 mM 
Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 1mM EDTA, 1mM 
EGTA, 1mM Na3VO4) supplemented with protease and phosphatase inhibitors (Roche). 
Cells were incubated on ice for 15 minutes and the lysates were clarified by centrifugation. 
Equal amounts of lysates (30-50μg) were subjected to SDS-PAGE, transferred onto a 
nitrocellulose membrane, blocked for 1 hour at room temperature in tris buffered saline with 
0.05% Tween-20 and 5% non-fat milk and incubated with the indicated antibodies 
overnight. Blots were incubated with the appropriate secondary antibody for 45 minutes at 
room temperature and developed using ECL detection reagent (GE).
Quantitative Real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen), digested with DNase I 
(Promega), and used for reverse transcription (SuperScript II kit, Invitrogen). All Taqman 
primers were obtained from Applied Biosystems. Expression levels of GusB were used to 
normalize the amount of the investigated transcripts.
Viral Production and Transduction
Virus was produced by transient transfection of 293T cells with pCL-10A1 (Imgenex) and a 
retroviral vector using Fugene at a 1:1 ratio. Viral supernatant was collected 24 and 48 hours 
post-transfection and concentrated using centrifugal filter units (Amicon Ultra, Millipore). 
Target cells were resuspended at 0.5×106 cells/ml in RPMI with viral supernatant in 6-well 
plates and spun at 2500 rpm for 1 hour at room temperature. Cells were incubated with viral 
supernatant for an additional 3 hours at 37°C and then plated in RPMI for an additional 
24-48 hours before harvest for experiments.
Results
Inhibition of IKKβ results in apoptosis of BCR-ABL-expressing cells
Recently, we and others have shown that IKKβ activity is required for survival of BCR-
ABL-expressing myeloid cells, including cells with mutations resistant to the commonly 
used BCR-ABL inhibitors Imatinib and Dasatinib (Duncan et al., 2008, Cilloni et al., 2006). 
That data showed the importance of IKKβ in BCR-ABL-induced oncogenesis. However a 
mechanism mediating IKK inhibitor-induced cell death and involvement of NF-κB in cell 
survival was not shown. As analyzed before, cell viability was measured to determine the 
effect of IKKβ inhibition using Compound A (a well validated IKKβ inhibitor, Ziegelbauer 
et al., 2005) in parental 32D cells and in 32D cells stably expressing BCR-ABL p185 (32D/
p185). Compound A treatment resulted in decreased cell viability similar to treatment with 
Imatinib, while Compound C, an inactive analog of Compound A, did not affect the viability 
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of 32D/p185 cells (Fig. 1A and see Duncan et al., 2008). The decrease in cell viability with 
Compound A treatment corresponds with cleavage of caspase 3, a marker of apoptosis (Fig. 
1B). Similar results were seen in parental BaF3 pro-B cells and BaF3 cells expressing BCR-
ABL (Fig. S1). Co-incubation with ZVAD-FMK, an inhibitor of caspase activation, potently 
blocks Compound A-induced cell death. These results show that IKKβ activity is required to 
block apoptosis in cells expressing BCR-ABL (Fig. 1B and Duncan et al, 2008).
NF-κB activity is required for the survival of BCR-ABL-expressing cells
Although IKKβ is known to activate NF-κB through the phosphorylation-mediated 
ubiquitination and degradation of IκBα, it also has other targets (Hu et al., 2004; Lee et al., 
2007). Therefore, to determine if NF-κB is necessary for the survival of BCR-ABL-
expressing cells downstream of IKKβ, and to rule out off target effects of Compound A, NF-
κB activity was blocked by expressing IκBα super-repressor (IκBα-SR), a form of IκBα 
containing serine to alanine mutations at residues 32 and 36 that prevent its phosphorylation 
and degradation, thereby sequestering NF-κB in the cytoplasm of the cell. Expression of 
IκBα-SR led to apoptosis in BCR-ABL-expressing 32D cells over time as measured by 
Annexin V/PI staining (Fig. 2A) and expression of cleaved caspase 3 (Fig. 2B) while the 
viability of cells transduced with empty vector were not affected. Taken together, these 
results show a requirement for NF-κB activity downstream of IKKβ in hematopoietic cells 
expressing BCR-ABL to prevent apoptosis.
IKKβ inhibition in BCR-ABL-expressing cells results in the accumulation of intracellular 
oxygen species
While the inhibition of both IKKβ and NF-κB in BCR-ABL-expressing cells results in 
apoptosis, the mechanism that precedes cell death remains unclear. Cells that have 
undergone oncogenic transformation, including those overexpressing Ras, c-myc and BCR-
ABL, have increased levels of intracellular ROS (Irani et al., 1997, Vafa et al. 2002, Sattler 
et al., 2000). Transformed cells utilize increased ROS as secondary signaling molecules to 
enhance proliferation and tumor development. However, because transformed cells harbor 
higher levels of ROS, a further increase in free radicals can result in apoptosis or necrosis 
(Pelicano et al, 2004). As BCR-ABL expression is known to enhance reactive oxygen 
species production in hematopoietic cells (Sattler et al, 2000; Kim et al, 2005; Naughton et 
al, 2009) and NF-κB can regulate antioxidant gene expression (Tang et al, 2002; Pham et al, 
2004; Kamata et al, 2005), we asked if IKKβ inhibition with Compound A results in altered 
ROS levels leading to cell death. Relative ROS levels were measured in 32D/p185 cells 
treated with Imatinib or Compound A over time. Treatment with the BCR-ABL inhibitor 
Imatinib decreased intracellular ROS levels (Fig. 3A) as previously reported (Sattler et al., 
2000), while IKKβ inhibition using Compound A caused an increase in intracellular ROS as 
measured by DCF-DA staining. Cells treated for 12 to 16 hours showed an accumulation of 
ROS (Fig. 3) while cells treated for 1 hour did not (data not shown), suggesting that an 
indirect mechanism leads to the accumulation of ROS in these cells. The accumulation of 
ROS upon treatment with Compound A is reversed through the addition of antioxidants n-
acetyl-cysteine (NAC) or butylated hydroxyanisole (BHA) (Fig. 3B). These data indicate 
that IKKβ inhibition leads to significantly enhanced levels of ROS, over those induced by 
BCR-ABL.
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NF-κB inhibits the activation of JNK downstream of BCR-ABL to promote cell survival
At high levels, ROS have been shown to activate AP-1, resulting in cell death (Shen and 
Liu, 2006). Interestingly, NF-κB is important for the regulation of JNK, an upstream 
effector of AP-1, to block death under cell stress conditions (Tang et al., 2002; Pham et al, 
2004; Kamata et al, 2005). Given the correlation between increased intracellular ROS and 
apoptosis in BCR-ABL-expressing cells after Compound A treatment, we asked if NF-κB 
activation is important for the regulation of intracellular ROS and inhibition of JNK 
downstream of BCR-ABL. A time course in which 32D/p185 cells were treated with 
Compound A shows that both the phosphorylation of JNK, its downstream target c-jun, and 
caspase-3 cleavage occur 6 hours after treatment (Fig. 4A). 32D/p185 cells were transduced 
with empty vector or IκBα-SR to examine the effect of NF-κB inhibition on JNK activation 
and apoptosis downstream of BCR-ABL. Cells harvested 36 hours post-transduction showed 
increased phosphorylation of JNK, c-jun and the cleavage of caspase 3 (Fig. 4B). Parental 
32D cells expressing IκBα-SR were not affected to the same extent as 32D/p185 cells, 
although some apoptosis is apparent as measured by cleavage of caspase 3 (Fig. 4C). This 
low level of cell death can be attributed to moderate activation of NF-κB in these cells due 
to their dependence on IL-3 for survival (Reuther et al., 1998). While IL-3 is also known to 
activate JNK (Yu et al., 2004), expression of IκBα-SR did affect JNK phosphorylation in 
these cells. Together, these data show that NF-κB actively regulates the level of intracellular 
ROS and also inhibits the activation of JNK downstream of BCR-ABL to inhibit cells from 
undergoing apoptosis.
IKKβ inhibition leads to downregulation of transcription of antioxidant genes
Our results show that NF-κB activity is important for the regulation of intracellular ROS and 
JNK activity downstream of BCR-ABL to prevent cells from undergoing apoptosis. NF-κB 
is known to regulate the expression of genes encoding proteins with antioxidant properties 
(Kamata et al., 2005; Pham et al, 2004). Due to the increase in intracellular ROS upon 
inhibition of IKKβ, we asked if NF-κB transcriptionally regulates genes known to clear 
excess ROS from the cell. BCR-ABL-expressing cells were treated with vehicle or 
Compound A and quantitative real-time PCR was used to screen NF-κB target genes known 
to have antioxidant properties. 32D/p185 cells treated with Compound A for 12 hours 
showed decreased levels of both Sod2 and Fth1 mRNAs (Fig. 5A), corresponding with the 
phosphorylation of JNK and apoptosis (Fig. 4A). This result indicates that blocking IKKβ 
activity results in decreased production of two known ROS scavengers, possibly resulting in 
accumulation of intracellular ROS and apoptosis. To rule out potential off target effects of 
Compound A, IκBα-SR was overexpressed to block NF-κB activity in 32D/p185 cells. 
Similar to the results obtained using Compound A treatment, cells expressing IκBα-SR (Fig. 
5C) also showed decreased mRNA levels of Sod2 and Fth1 (Fig. 5B), correlating with 
apoptosis as measured by cleavage of caspase 3. Overexpression of Sod2 and Fth1 did not 
rescue the cell death response induced by IKKβ inhibition (data not shown), suggesting that 
multiple mechanisms controlled by IKK and NF-κB contribute to the control of ROS levels 
in oncogenically transformed cells.
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JNK inhibition rescues BCR-ABL+ cells from apoptosis after Compound A treatment
Our results show that NF-κB activity regulates intracellular ROS levels and JNK activation 
in BCR-ABL-expressing cells. To determine the importance of JNK activity in the death of 
BCR-ABL-expressing cells after inhibition of NF-κB, we blocked JNK using a specific 
inhibitor, SP600125, and treated 32D/p185 cells with Compound A. Cells that were treated 
with SP600125 and Compound A showed decreased apoptosis as indicated by caspase 3 
cleavage (Fig. 6A) and FACS analysis (Fig. 6B). However, cells treated with high 
concentrations of SP600125 (≥25μM) underwent apoptosis without IKKβ inhibition, 
indicating that BCR-ABL-expressing cells also require low levels of JNK activity for 
survival as previously shown (Raitano et al, 1995; Hess et al., 2002). Similar results were 
obtained from 32D/p185 cells that were treated with SP600125 upon expression of IκBα-SR 
(Fig. 6C). These data show that increased JNK activity is required for cell death in BCR-
ABL-expressing cells when NF-κB is inhibited. These data further suggest an important role 
for JNK regulation and evasion of apoptosis by NF-κB downstream of BCR-ABL.
Inhibition of ROS prevents death due to IKKβ inhibition in BCR-ABL+ cells
The increase in intracellular ROS in transformed cells enhances proliferation and 
tumorigenicity. However, these cells are also sensitive to further increases in intracellular 
ROS, which may lead to apoptosis (Pelicano et al, 2004). Our data show that inhibition of 
NF-κB leads to a further increase in intracellular ROS, activation of JNK and apoptosis 
downstream of BCR-ABL. To better understand the role of NF-κB in the regulation of 
intracellular ROS in cells expressing BCR-ABL, we inhibited ROS and measured cell death 
after Compound A treatment. Interestingly, 32D/p185 cells incubated with n-acetyl-cysteine 
(NAC) or butylated hydroxyanisole (BHA) in conjunction with Compound A treatment 
showed a pronounced decrease in phosphorylated JNK and were resistant to apoptosis (Fig. 
7A and 7B). Similar results were obtained in Ba/F3 cells expressing BCR-ABL (Fig. S2). 
Cells were also coincubated with bovine catalase and Compound A, resulting in decreased 
JNK phosphorylation and apoptosis (Fig. 7C). Lastly, 32D/p185 cells were incubated with 
NAC upon expression of IκBα-SR as determined by GFP expression. JNK activation and 
apoptosis induced by the overexpression of IκBα-SR were also inhibited by NAC treatment 
(Fig. 7D). These results show that NF-κB activity is required to regulate increased 
intracellular ROS following transformation with BCR-ABL. Upon inhibition of NF-κB, the 
accumulation of ROS in the cell leads to the activation of JNK and apoptosis (Fig. 7E).
Discussion
Increased ROS has been documented in several cell types after oncogenic transformation 
and in various cancers (Benhar et al., 2002, Pelicano et al., 2004). It was first discovered that 
human tumor cells produce increased amounts of hydrogen peroxide (Szatrowski and 
Nathan, 1991), leading to the hypothesis that cancer cells are subject to persistent oxidative 
stress, possibly explaining characteristics of cancer including genomic instability and 
increased proliferation (Toyokuni et al., 1995). Indeed, several reports have shown an 
increase in reactive oxygen species in primary human tumors, including brain (Iida et al., 
2001), colorectal carcinoma (Toyokuni et al., 1999), and ovarian cancer (Senthil et al., 
2004). Additionally, reports showed that oncogenic transformation by Ras, c-myc and BCR-
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ABL lead to increased ROS which important for increased proliferation and tumorigenic 
potential (Irani et al., 1997; Felsher et al., 1999; Vafa et al., 2002, Sattler et al., 2000; Kim et 
al, 2005; Naughton et al, 2009).
Relative to oncogenic Ras expression, increased ROS levels were shown to be required for 
cellular transformation (Irani et al., 1997). In this regard, ROS generated from the Qo site of 
mitochondrial complex III is required for anchorage-independent growth of Ras-transformed 
cells (Weinberg et al, 2010). Overexpression of Nox1, a superoxide generator, in NIH3T3 
results in elevated production of ROS and a transformed phenotype with increased 
proliferation (Suh et al., 1999). Interestingly, Nox1 knockdown blocks Ras-transformed 
phenotypes including anchorage independent growth in vitro and in vivo (Mitsushita et al., 
2004). Relative to our study, ROS levels are increased downstream of BCR-ABL which 
leads to increased PI3K/Akt-dependent signaling through inhibition of the phosphatase PP1a 
(Naughton et al., 2009).
Cells transformed with BCR-ABL have increased ROS (Sattler et al, 2000; Kim et al, 2005; 
Naughton et al, 2009) (and see Fig. 3A ) thus increasing the sensitivity of these cells to a 
further increase in ROS. Treatment with agents that cause an increase in ROS in BCR-ABL-
expressing cells causes to death (Zhou et al, 2003; Chandra et al., 2006; Trachootham et al., 
2006; Zhang et al., 2008; Mao et al, 2010). One such agent, phenethyl isothiocyanate 
(PEITC) results in increased ROS and subsequent apoptosis in cells expressing both wild-
type (Trachootham et al., 2006) and Imatinib- and Dasatinib-resistant (Zhang et al., 2008) 
forms of BCR-ABL. However, the mechanism by which these compounds cause increased 
ROS and cell death is largely unknown.
Data described above indicate that the maintenance of moderate levels of ROS are necessary 
for increased proliferative capacity and tumorigenic potential while avoiding death in 
response to excessive accumulation of free radicals (Schimmel and Bauer., 2002; Benhar et 
al., 2002; Pelicano et al., 2004). Due to excessive strain on ROS clearing mechanisms that 
maintain a moderate balance of ROS, a further increase in ROS in transformed cells may 
result in cancer cell death (Benhar et al., 2002; Pelicano et al. 2004), offering a novel 
approach to target cancer cells.
Potential therapeutic targets to increase ROS specifically in cancer cells include 
transcription factors that control the expression of both antiapoptotic and antioxidant genes. 
One such transcription factor, NF-κB, has been shown to regulate the transcription of genes 
with antioxidant properties, such as ferritin heavy chain (Pham et al., 2004) and superoxide 
dismutates (Kamata et al., 2005). NF-κB also inhibits JNK activation downstream of ROS 
through transcription of genes such as Gadd45 (De Smaele et al., 2001) and XIAP (Tang et 
al., 2001) and through the inhibition of MAPK (Kamata et al., 2005) and tyrosine 
phosphatases (Sattler et al., 2000).
Our results show an important role for NF-κB activity in the maintenance of intracellular 
ROS and the inhibition of JNK activity downstream of BCR-ABL to prevent cell death after 
oncogenic transformation. Inhibition of IKKβ using a chemical inhibitor, Compound A, 
results in apoptosis (Fig. 1), along with the accumulation of intracellular ROS and the 
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activation of JNK in BCR-ABL-expressing cells (Fig. 3). Likewise, expression of IκBα-SR, 
which blocks NF-κB activity, induces JNK phosphorylation and apoptosis (Fig. 4B). These 
data correlate with previous reports in which NF-κB plays an important role in JNK 
inhibition when ROS levels increase (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 
2005).
Treatment with Compound A or expression of IκBα-SR also results in decreased expression 
of two NF-κB target genes with antioxidant properties, Fth1 and Sod2 (Fig. 5). These genes 
have been documented in response to TNFα stimulation in which TNFα-induced ROS was 
scavenged thereby protecting cells from TNFα induced death in the absence of NF-κB 
(Pham et al., 2004, Kamata et al., 2005). While inhibition of NF-κB results in decreased 
antioxidant gene expression (Fth1 and Sod2), our preliminary data indicates that 
overexpression of either FTH1 or SOD2 in BCR-ABL-expressing cells is not sufficient to 
inhibit apoptosis in the absence of NF-κB activity. This is not surprising, as many cellular 
processes control the levels of ROS, indicating that other NF-κB-dependent genes and 
buffering systems are likely involved in this process.
Our data also show that JNK activity is involved in the initiation of apoptosis in the absence 
of NF-κB. Blocking JNK activity with a chemical inhibitor, SP600125, results in a decrease 
in cell death upon Compound A treatment downstream of BCR-ABL (Fig. 6). However, 
cells expressing BCR-ABL appear to require JNK activity, as the inhibitor alone results in 
induction of apoptosis in 32D/p185 cells. Importantly, JNK activation by ROS is required 
for the initiation of apoptosis in the absence of NF-κB activity (Fig. 7). However, inhibition 
of ROS with antioxidants offers more complete protection from Compound A-induced 
apoptosis that inhibition of JNK with SP600125. This could simply be due to the efficiency 
of inhibition by these compounds, or the differences in survival could indicate a more 
involved role for increased ROS in apoptosis after inhibition of NF-κB. It is probable that 
ROS activate JNK as well as other proteins in the cell to initiate apoptosis in response to 
unfavorable conditions, and that inhibiting JNK only partially blocks the effect of increased 
ROS on cell survival.
These data show that NF-κB is required to maintain moderate levels of ROS and inhibit 
JNK activation downstream of BCR-ABL-induced ROS to inhibit the induction of apoptosis 
in a model of chronic myeloid leukemia. As increased ROS is common among transformed 
cells, it is likely that NF-κB plays an essential role in the regulation of ROS to prevent 
death, illustrating the potential use for IKKβ inhibitors as a therapeutic in CML and possibly 
other cancers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Inhibition of IKKβ causes apoptosis in BCR-ABL-expressing myeloid cells
(A) 32D cells expressing BCR-ABL (32D/p185) were incubated with 1μM Imatinib, IKK 
inhibitor (Compound A) or inactive analog of Compound A (Compound C) for 20 hours. 
Cell viability was measured by MTS reduction. (B) 32D/p185 cells were coincubated with 
Z-VAD-FMK (100μM) and DMSO (vehicle control) or Compound A for 20 hours. Cells 
were stained with propidium iodide and annexin V and cell death was measured by FACS 
analysis or (C) lysed and analyzed by immunoblot.
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Figure 2. NF-κB activity is required for survival of BCR-ABL-expressing cells
(A) 32D/p185 cells were transduced with retrovirus expressing vector control or IκBα 
superrepressor (IκBα-SR). Cells were harvested 36 hours after retroviral transduction and 
stained with propidium iodide and Annexin V. Cell death was analysed by FACS, or (B) 
analyzed by immunoblot.
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Figure 3. Inhibition of NF-κB causes an increase in intracellular ROS in cells expressing BCR-
ABL
(A) 32D/p185 cell were incubated with DMSO (vehicle control) or 1μM Imatinib or 
Compound A for 16 hours without or (B) with antioxidants. Cells were then incubated with 
DCF-DA and fluorescence was measured my FACS analysis.
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Figure 4. IKKβ inhibition downstream of BCR-ABL induces JNK activation and apoptosis
(A) 32D/p185 cells were treated with DMSO or 1μM Compound A over a time course. Cells 
were lysed and subjected to immunoblotting. (B) 32D/p185 or (C) parental 32D cells were 
transduced with retrovirus expressing vector control or IκBα superrepressor (IκBα-SR) and 
harvested 36 hours after retroviral transduction, lysed and subjected to immunoblotting.
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Figure 5. NF-κB regulates antioxidant gene expression in BCR-ABL-expressing cells
(A) 32D/p185 cells were treated for 12 hours with DMSO or 1μM Compound A. RNA was 
purified using Trizol and then subjected to reverse transcription before analysis using 
quantitative real-time PCR. (B) 32D/p185 cells transduced with retrovirus expressing empty 
vector or IκBα-SR. Gene expression was analyzed by quantitative real-time PCR as 
described. (C) Expression levels of IκBα of cells used in panel B.
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Figure 6. JNK activation in the absence of NF-κB activity leads to apoptosis in BCR-ABL-
expressing cells
(A) 32D/p185 cells were pretreated with vehicle or indicated concentrations of SP600125 
for 1 hour. 1μM Compound or DMSO were then added and cells were incubated for an 
additional 24 hours. Cells were then harvested, lysed and subjected to immunoblot. (B) 32D/
p185 cells were incubated with vehicle or 25 μM SP600125 for 1 hour prior to the addition 
of DMSO of 1μM Compound A. Cells were stained using Annexin V and propidium iodide. 
Cell death was measured by FACS. (C) 32D/p185 cell were transduced with IκBα-SR. 20 
hours post-transduction, cells were treated with SP600125 additional 8 hours. Cells were 
then lysed and analyzed by immunoblot.
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Figure 7. Antioxidants rescue BCR-ABL-expressing cells from death when NF-κB is inhibited
32D/p185 cells were pretreated with vehicle, 20mM NAC or 50μM BHA for 1 hour prior to 
the addition of DMSO or 1μM Compound A. Cells were incubated for an additional 20 
hours and (A) lysed and subjected to immunoblot, or (B) stained with Annexin V and 
propidium iodide and analyzed using flow cytometry. (C) 32D/p185 cells were pretreated 
with bovine catalase for 1 hour prior to the addition of DMSO or 1μM Compound A. Cells 
were incubated for an additional 20 hours and then harvested for immunoblot. (D) 32D/p185 
cells were transduced with retrovirus expressing empty vector or IκBα-SR. 24 hours after 
transduction, cells were replated in media with or without 20μM NAC for an additional 12 
hours. Cells were harvested, lysed and used for immunoblotting. E. Model showing the role 
of NF-κB in the regulation of intracellular ROS in BCR-ABL-expressing cells.
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